A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations
H Yoshioka, H Hayashi, K Kiura, N Takigawa… - Journal of Clinical …, 2009 - ascopubs.org
8067 Background: Efficacy of gefitinib therapy strongly depends on the presence of active
EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and …
EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and …
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
MC Garassino, O Martelli, A Bettini, I Floriani… - 2012 - ascopubs.org
LBA7501 Background: While the benefit of EGFR tyrosine kinase inhibitors in the treatment
of patients with NSCLC harboring EGFR mutations has been widely established, their value …
of patients with NSCLC harboring EGFR mutations has been widely established, their value …
[HTML][HTML] Gefitinib First or Gefitinib Second: Is Timing Everything in the Treatment of EGFR Mutant Non–Small Cell Lung Cancer?
PA Jänne - American journal of respiratory and critical care …, 2008 - atsjournals.org
Somatic mutations in the epidermal growth factor receptor (EGFR) have emerged as
important biomarkers in predicting the likelihood of tumor response to the EGFR tyrosine …
important biomarkers in predicting the likelihood of tumor response to the EGFR tyrosine …
[HTML][HTML] Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
F Hirai, M Edagawa, S Shimamatsu… - Oncology …, 2017 - spandidos-publications.com
Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
[HTML][HTML] Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung …
N Yamamoto, K Goto, M Nishio, K Chikamori… - International Journal of …, 2017 - Springer
Abstract Background In Japan, the clinical efficacy of erlotinib monotherapy in epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
P76. 10 Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
T Chu, W Zhang, B Zhang, R Zhong, C Shi… - Journal of Thoracic …, 2021 - jto.org
Methods In this open-label, phase 2 study, NSCLC patients with previously untreated, EGFR
mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21 …
mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21 …
[HTML][HTML] Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer
Objectives In 2008, we initiated a prospective study to explore the frequency and predictive
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non–small-cell lung cancer
AG Pallis, A Voutsina, N Kentepozidis, S Giassas… - Clinical Lung Cancer, 2012 - Elsevier
Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …